Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2015 Nov 20

PMID 26583156

Citations 24

Authors

Cleo Goyvaerts

Karine Breckpot

Affiliations

Soon will be listed here.

Abstract

In therapeutic antitumor vaccination, dendritic cells play the leading role since they decide if, how, when, and where a potent antitumor immune response will take place. Since the disentanglement of the complexity and merit of different antigen-presenting cell subtypes, antitumor immunotherapeutic research started to investigate the potential benefit of targeting these subtypes in situ. This review will discuss which antigen-presenting cell subtypes are at play and how they have been targeted and finally question the true meaning of targeting antitumor-based vaccines.

Citing Articles

Cancer immunotherapy and its facilitation by nanomedicine.

Sui C, Wu H, Li X, Wang Y, Wei J, Yu J Biomark Res. 2024; 12(1):77.

PMID: 39097732 PMC: 11297660. DOI: 10.1186/s40364-024-00625-6.

Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy.

Babamohamadi M, Mohammadi N, Faryadi E, Haddadi M, Merati A, Ghobadinezhad F Cell Death Dis. 2024; 15(1):17.

PMID: 38191571 PMC: 10774412. DOI: 10.1038/s41419-023-06391-x.

Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice.

Matsuda T, Misato K, Tamiya S, Akeda Y, Nakase I, Kuroda E iScience. 2022; 25(11):105324.

PMID: 36304121 PMC: 9593262. DOI: 10.1016/j.isci.2022.105324.

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Wang D, Wu X, Sun Y Signal Transduct Target Ther. 2022; 7(1):331.

PMID: 36123348 PMC: 9485144. DOI: 10.1038/s41392-022-01136-2.

New Generation Vaccines for COVID-19 Based on Peptide, Viral Vector, Artificial Antigen Presenting Cell, DNA or mRNA.

Rezaei M, Nazari M Avicenna J Med Biotechnol. 2022; 14(1):30-36.

PMID: 35509358 PMC: 9017465. DOI: 10.18502/ajmb.v14i1.8167.

References

Moyle P, Olive C, Ho M, Pandey M, Dyer J, Suhrbier A . Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J Med Chem. 2007; 50(19):4721-7. DOI: 10.1021/jm070287b. View

Palucka K, Banchereau J, Mellman I . Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010; 33(4):464-78. PMC: 2975953. DOI: 10.1016/j.immuni.2010.10.007. View

Rosalia R, Cruz L, van Duikeren S, Tromp A, Silva A, Jiskoot W . CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 2014; 40:88-97. DOI: 10.1016/j.biomaterials.2014.10.053. View

Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C . The ReNAissanCe of mRNA-based cancer therapy. Expert Rev Vaccines. 2014; 14(2):235-51. DOI: 10.1586/14760584.2015.957685. View

Mockey M, Bourseau E, Chandrashekhar V, Chaudhuri A, Lafosse S, Cam E . mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 2007; 14(9):802-14. DOI: 10.1038/sj.cgt.7701072. View

Muyldermans S . Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013; 82:775-97. DOI: 10.1146/annurev-biochem-063011-092449. View

Froyland M, Ruffini P, Thompson K, Gedde-Dahl T, Fredriksen A, Bogen B . Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing. Eur J Haematol. 2011; 86(5):385-95. DOI: 10.1111/j.1600-0609.2011.01590.x. View

Wang B, Kuroiwa J, He L, Charalambous A, Keler T, Steinman R . The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann N Y Acad Sci. 2009; 1174:6-17. PMC: 2933265. DOI: 10.1111/j.1749-6632.2009.04933.x. View

Aranda F, Llopiz D, Diaz-Valdes N, Riezu-Boj J, Bezunartea J, Ruiz M . Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res. 2011; 71(9):3214-24. DOI: 10.1158/0008-5472.CAN-10-3259. View

10.

Kawai T, Akira S . Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci. 2008; 1143:1-20. DOI: 10.1196/annals.1443.020. View

11.

Bol K, Tel J, de Vries I, Figdor C . Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology. 2013; 2(3):e23431. PMC: 3661171. DOI: 10.4161/onci.23431. View

12.

Muraoka D, Harada N, Hayashi T, Tahara Y, Momose F, Sawada S . Nanogel-based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity. ACS Nano. 2014; 8(9):9209-18. DOI: 10.1021/nn502975r. View

13.

Cui Z, Han S, Huang L . Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm Res. 2004; 21(6):1018-25. DOI: 10.1023/b:pham.0000029292.66792.4f. View

14.

Vos J, Devoogdt N, Lahoutte T, Muyldermans S . Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. Expert Opin Biol Ther. 2013; 13(8):1149-60. DOI: 10.1517/14712598.2013.800478. View

15.

Li M, Husic N, Lin Y, Christensen H, Malik I, McIver S . Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods. 2010; 189(1):56-64. PMC: 2864797. DOI: 10.1016/j.jneumeth.2010.03.019. View

16.

Bachem A, Hartung E, Guttler S, Mora A, Zhou X, Hegemann A . Expression of XCR1 Characterizes the Batf3-Dependent Lineage of Dendritic Cells Capable of Antigen Cross-Presentation. Front Immunol. 2012; 3:214. PMC: 3399095. DOI: 10.3389/fimmu.2012.00214. View

17.

Barton G, Kagan J . A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009; 9(8):535-42. PMC: 3934928. DOI: 10.1038/nri2587. View

18.

Coquerelle C, Moser M . DC subsets in positive and negative regulation of immunity. Immunol Rev. 2010; 234(1):317-34. DOI: 10.1111/j.0105-2896.2009.00887.x. View

19.

Seavey M, Pan Z, Maciag P, Wallecha A, Rivera S, Paterson Y . A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res. 2009; 15(3):924-32. DOI: 10.1158/1078-0432.CCR-08-2283. View

20.

Biragyn A, Tani K, Grimm M, Weeks S, Kwak L . Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol. 1999; 17(3):253-8. DOI: 10.1038/6995. View